Responses
Regular and Young Investigator Award Abstracts
Clinical Trials Completed
383 Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695
Compose a Response to This Article
Other responses
No responses have been published for this article.